Alzheimer's and Aducanumab: Unjust Profits and False Hopes
Accelerated approval of aducanumab for mild Alzheimer's by the U.S. Food and Drug Administration on June 7, 2021, has generated substantial medical, scientific, and ethical controversy. That approval was contrary to the nearly unanimous judgment of the FDA's Advisory Committee that little...
| Main Author: | |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Wiley
2021
|
| In: |
The Hastings Center report
Year: 2021, Volume: 51, Issue: 4, Pages: 9-11 |
| Further subjects: | B
Medicare
B U.S. Food and Drug Administration B aducanumab B Professional Ethics B false hopes B Alzheimer's |
| Online Access: |
Volltext (kostenfrei) Volltext (kostenfrei) |